Three-minute constant rate step test for detecting exertional dyspnea relief after bronchodilation in COPD

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 2991-3000

  Borel, Benoit ^a,b   Wilkinson Maitland, Courtney A ^c   Hamilton, Alan ^d   Bourbeau, Jean ^e   Perrault, Hélène ^f   Jensen, Dennis ^c,e,g   Maltais, François ^b  

^a UNIVERSITÉ DE LIMOGES   (France)

^b LAVAL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Chronic obstructive pulmonary disease; Dyspnea; Exercise testing; Intervention

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; PLACEBO; SODIUM CHLORIDE; THEOPHYLLINE; MUSCARINIC RECEPTOR BLOCKING AGENT; SALBUTAMOL;

AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; THREE MINUTE CONSTANT RATE STEP TEST; CLINICAL TRIAL; CONVALESCENCE; DRUG EFFECTS; EXERCISE TOLERANCE; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; MULTICENTER STUDY; NEBULIZER; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUEBEC; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSPNEA; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NEBULIZERS AND VAPORIZERS; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUEBEC; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85007497434     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S113113     Document Type: Article

References (34)

1. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.
2. O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J. 2007;14(suppl B):5B-32B.
3. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4): 347-365.
4. Borel B, Provencher S, Saey D, Maltais F. Responsiveness of various exercise-testing protocols to therapeutic interventions in COPD. Pulm Med. 2013;2013:410748.
5. Brouillard C, Pepin V, Milot J, Lacasse Y, Maltais F. Endurance shuttle walking test: responsiveness to salmeterol in COPD. Eur Respir J. 2008; 31(3):579-584.
6. O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832-840.
7. O’Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004;24(1):86-94.
8. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128(3):1168-1178.
9. Casaburi R, Maltais F, Porszasz J, et al. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(9): 1351-1361.
10. Zhang X, Waterman LA, Ward J, Baird JC, Mahler DA. Advantages of endurance treadmill walking compared with cycling to assess bronchodilator therapy. Chest. 2010;137(6):1354-1361.
11. Perrault H, Baril J, Henophy S, Rycroft A, Bourbeau J, Maltais F. Paced-walk and step tests to assess exertional dyspnea in COPD. COPD. 2009;6(5):330-339.
12. Lahaije AJ, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Physiologic limitations during daily life activities in COPD patients. Respir Med. 2010;104(8):1152-1159.
13. Vaes AW, Wouters EF, Franssen FM, et al. Task-related oxygen uptake during domestic activities of daily life in patients with COPD and healthy elderly subjects. Chest. 2011;140(4):970-979.
14. Castro AA, Porto EF, Iamonti VC, de Souza GF, Nascimento OA, Jardim JR. Oxygen and ventilatory output during several activities of daily living performed by COPD patients stratified according to disease severity. PLoS One. 2013;8(11):e79727.
15. Sava F, Perrault H, Brouillard C, et al. Detecting improvements in dyspnea in COPD using a three-minute constant rate shuttle walking protocol. COPD. 2012;9(4):395-400.
16. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest. 1994;105(5): 1411-1419.
17. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med. 1995;152(5 pt 2):S77-S121.
18. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5-40.
19. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179-187.
20. Gandevia B, Hugh-Jones P. Terminology for measurements of ventilatory capacity; a report to the thoracic society. Thorax. 1957;12(4): 290-293.
21. O’Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(5):770-777.
22. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-381.
23. American Thoracic Society; American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2):211-277.
24. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD. 2005;2(1):105-110.
25. O’Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(5 pt 1): 1557-1565.
26. O’Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 160(2):542-549.
27. Pepin V, Saey D, Whittom F, LeBlanc P, Maltais F. Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(12):1517-1522.
28. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;31(4):742-750.
29. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23): 2222-2234.
30. O’Donnell DE, Banzett RB, Carrieri-Kohlman V, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc. 2007;4(2):145-168.
31. O’Donnell DE, Hamilton AL, Webb KA. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. J Appl Physiol. 2006;101(4):1025-1035.
32. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153(3):967-975.
33. Faisal A, Alghamdi BJ, Ciavaglia CE, et al. Common mechanisms of dyspnea in chronic interstitial and obstructive lung disorders. Am J Respir Crit Care Med. 2016;193(3):299-309.
34. Casaburi R, Rennard SI. Exercise limitation in chronic obstructive pulmonary disease. The O’Donnell threshold. Am J Respir Crit Care Med. 2015;191(8):873-875.